Programs
Breast Cancer
Colorectal Cancers
ctDNA/MRD
Genitourinary Cancers
GI Cancers
Biliary Tract Cancers
Gastroesophageal Cancers
Liver Cancer
Pancreatic Cancer
Gynecologic Cancer
Hematologic Cancers
Lung Cancer
Melanoma
Precision Medicine
ALK
BRAF
BRCA
c-MET
EGFR
ESR1
FGFR
HER2
KRAS
MTAP
NRG1 Fusions
NTRK Fusions
Faculty
Tumor Boards
Newsletters
Resources
About Us
Search
Genitourinary Cancers
Precision Oncology in Bladder Cancer: FGFR3 Inhibitors
Tian Zhang, MD, MHS
Integrating Precision Oncology in Prostate Cancer: Current Role of PARP Inhibitors and Combinations
Tian Zhang, MD, MHS
2025 Update on Management of NTRK Fusions
Martin F. Dietrich, MD, PhD
The Emerging Role of ctDNA in the Treatment of Bladder Cancer
John P. Sfakianos, MD
Prostate Cancer with NTRK Fusion
Martin F. Dietrich, MD, PhD
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website
